Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
110 stopped studies mapped to Malignant Solid Neoplasm and descendants · 95% state a reason
Over the 110 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell… | Phase 1 | withdrawn | Jul 14, 2017 | National Cancer Institute (NCI) | Other - Drug Manufacturer decision to close study | Drug supply |
| NCT02045095 | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid… | Phase 1 | terminated | Jan 24, 2014 | Millennium Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00997360 | Study of PKI-179 Administered Orally to Subjects With Solid Tumors | Phase 1 | withdrawn | Oct 19, 2009 | Wyeth is now a wholly owned subsidiary of Pfizer | not stated | Not stated |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced… | Phase 1 / Phase 2 | withdrawn | Oct 31, 2017 | National Cancer Institute (NCI) | The study itself was Disapproved on 04/20/2018 and will not be moving forward. | Other (stated, no rule matched) |
| NCT01632696 | Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced… | Early Phase 1 | terminated | Jul 3, 2012 | Peregrine Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT00977067 | A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to… | Phase 1 | terminated | Sep 15, 2009 | Genentech, Inc. | The study was terminated early by the Sponsor for reasons unrelated to patient safety or anti-tumor… | Safety / toxicity |
| NCT02096341 | A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration… | Phase 1 | terminated | Mar 26, 2014 | EpicentRx, Inc. | Subcutaneous administration of RRx-001 is no longer of interest. | Other (stated, no rule matched) |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | Phase 1 | terminated | May 3, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Drugs unavailable. Study did not progress to Phase 2. | Other (stated, no rule matched) |
| NCT00337376 | A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With… | Phase 1 | terminated | Jun 15, 2006 | Yale University | not stated | Not stated |
| NCT01416623 | A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies | Phase 1 | terminated | Aug 15, 2011 | Jiangsu HengRui Medicine Co., Ltd. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Feb 7, 2020source: clinicaltrials